A Trial Comparing Insulin Degludec/Liraglutide and Insulin Degludec in Combination With Metformin in Chinese Subjects With Type 2 Diabetes Mellitus Inadequately Controlled With Basal Insulin Therapy and Metformin With or Without One Other Oral Antidiabetic Drug (OAD)

NCT03175120 · Completed

Last updated 2026-05-28

This clinical trial compares two diabetes treatments—insulin degludec/liraglutide and insulin degludec combined with metformin—in adults with type 2 diabetes whose blood sugar is not well controlled by basal insulin and metformin, with or without another oral diabetes medication.

Status Completed The study has finished.

Phase Phase 3 Confirms effectiveness in a large group before approval.

Type Interventional (clinical trial)

Design Randomized, double-blind treatment study

Participants 453 people

Who can join Ages 18+ · all sexes

Timeline Started 2017-05 · est. completion 2019-04

Where 37 sites · China, Hong Kong

What this study is testing ClinicalTrials.gov NCT03175120 ↗

Description as written by the study sponsor.

This trial is conducted in Asia. The aim of this trial is to confirm the superiority of insulin degludec/liraglutide versus insulin degludec in controlling glycaemia in Chinese subjects with type 2 diabetes mellitus after 26 weeks of treatment

Treatments tested

Insulin degludec/liraglutide Drug

Administered subcutaneously (s.c., under the skin) once daily in combination with metformin for the treatment duration of 26 weeks.
Insulin degludec Drug

Administered subcutaneously (s.c., under the skin) once daily in combination with metformin for the treatment duration of 26 weeks.

Main thing measured	Change in HbA1c
Sponsor	Novo Nordisk A/S
Conditions studied	Diabetes, Diabetes Mellitus, Type 2
GLP-1 drugs	liraglutide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT03175120 ↗